Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

Lucile Neyton, Ravi K. Patel, Aartik Sarma, K. Mark Ansel, Stephanie A. Christenson, Michael Adkisson, Walter L. Eckalbar, Lenka Maliskova, Andrew Schroeder, Raymund Bueno, M. Grace Gordon, George C. Hartoularos, Divya Kushnoor, David Lee, Elizabeth McCarthy, Anton Ogorodnikov, Matthew H. Spitzer, Kamir Hiam, Yun S. Song, Yang Sun, Erden Tumurbaatar, Monique G.p. van der Wijst, Alexander Whatley, Chayse Jones, Saharai Caldera, Catherine DeVoe, Paula Hayakawa Serpa, Christina Love, Eran Mick, Maíra Phelps, Alexandra Tsitsiklis, Carolyn Leroux, Sadeed Rashid, Nicklaus Rodriguez, Kevin Tang, Luz Torres Altamirano, Aleksandra Leligdowicz, Michael A. Matthay, Michael R. Wilson, Chun Ye, Suzanna Chak, Rajani Ghale, Alejandra Jáuregui, Deanna Lee, Nguyễn Hoàng Việt, Austin Sigman, Kirsten N. Kangelaris, Saurabh Asthana, Zachary Collins, Arjun A. Rao, Bushra Samad, Cole Shaw, Tasha Lea, Alyssa Ward, Norman L. Jones, Jeff Milush, Vincent Chan, Nayvin W. Chew, Alexis J. Combes, Tristan Courau, Kenneth H. Hu, Billy Huang, Nitasha Kumar, Salman Mahboob, Priscila Muñoz-Sandoval, Randy Parada, Gabriella C. Reeder, Alan Shen, Jessica Tsui, Beth Shoshana Zha, Wandi S. Zhu, Andrew Willmore, Sidney C. Haller, David J. Erle, Matthew F. Krummel, Carolyn M. Hendrickson, Prescott G. Woodruff, Charles Langelier, Carolyn S. Calfee, Gabriela K. FragiadakisNature Communications 2024 · DOI

Abstract

Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk and single-cell RNA sequencing of samples from the lower respiratory tract and blood, and assess plasma cytokine profiling to study the effects of dexamethasone on both systemic and pulmonary immune cell compartments. In blood samples, dexamethasone is associated with decreased expression of genes associated with T cell activation, including TNFSFR4 and IL21R. We also identify decreased expression of several immune pathways, including major histocompatibility complex-II signaling, selectin P ligand signaling, and T cell recruitment by intercellular adhesion molecule and integrin activation, suggesting these are potential mechanisms of the therapeutic benefit of steroids in COVID-19. We identify additional compartment- and cell- specific differences in the effect of dexamethasone that are reproducible in publicly available datasets, including steroid-resistant interferon pathway expression in the respiratory tract, which may be additional therapeutic targets. In summary, we demonstrate compartment-specific effects of dexamethasone in critically ill COVID-19 patients, providing mechanistic insights with potential therapeutic relevance. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.

Introduction

Since the landmark RECOVERY trial, dexamethasone (Dex) has been the cornerstone of treatment for severe COVID-19. Despite its widespread use, the precise cellular and molecular mechanisms underlying its clinical benefit—particularly within the lungs—have remained elusive. A major challenge in treating Acute Respiratory Distress Syndrome (ARDS) is "compartmentalization," where the immune response in the blood may not reflect the local inflammatory environment of the respiratory tract. This study aims to bridge this gap by providing a high-resolution map of how dexamethasone reshapes the immune landscape across both systemic and pulmonary compartments.

Methods

Researchers conducted a prospective case-control study using the UCSF COMET cohort, analyzing 27 critically ill COVID-19 patients. The cohort included patients who received dexamethasone as standard of care and those who did not.

Study design and sampling timeline for COVID-19 patients treated with or without dexamethasone.

The study utilized a multi-omic approach:

  • Compartmental Sampling: Simultaneous collection of peripheral blood and tracheal aspirate (TA).
  • Transcriptomics: Bulk RNA sequencing of PBMCs and single-cell RNA sequencing (scRNA-seq) of blood and lung cells.
  • Proteomics: Plasma cytokine profiling of 18 inflammatory markers.
  • Integrative Analysis: Use of the DIABLO framework and CellChat for cell-cell communication modeling.

Findings were validated using external datasets from Sinha et al. (blood) and Liao et al. (bronchoalveolar lavage).

Results

Systemic Cytokine and Transcriptomic Shifts

Dexamethasone treatment was associated with a significant reduction in systemic inflammation. Plasma levels of pro-inflammatory cytokines IL-6 and IFN-gamma were markedly lower in the Dex group, while the anti-inflammatory cytokine IL-10 was increased. Transcriptomic analysis of blood revealed over 4,000 differentially expressed genes, with significant downregulation of T-cell activation markers such as TNFSFR4 (OX40) and IL21R.

Systemic cytokine levels and transcriptomic changes associated with dexamethasone treatment.

The "Interferon Discordance"

A key discovery was the discordance in interferon signaling between compartments. While Dex effectively suppressed IFN-gamma protein levels in the blood, interferon-stimulated genes (ISGs) remained highly expressed in the lungs. This "steroid-resistant" pulmonary interferon signaling suggests that local inflammation persists despite systemic treatment.

Pulmonary-Specific Effects

In the lungs, Dex was associated with decreased MHC-II signaling and reduced activity of SELPLG (P-selectin glycoprotein ligand-1), a known risk factor for ARDS. Conversely, neutrophils showed a consistent (concordant) response across both blood and lungs, with Dex decreasing pro-inflammatory S100A gene expression.

Discussion

This study highlights that dexamethasone's effects are not uniform across the body. The identification of steroid-resistant interferon signaling in the lungs suggests that current treatments may leave local "fires" burning. These findings provide a biological rationale for "Dex-plus" strategies, such as combining steroids with JAK/STAT inhibitors to more effectively quench pulmonary inflammation.

While the study is limited by its observational nature and relatively small sample size, the reproducibility of the findings across independent datasets underscores their robustness. Future research should continue to focus on compartmentalized immune responses to develop more targeted therapies for severe respiratory viral infections.

Summary updated

Abstract

Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk and single-cell RNA sequencing of samples from the lower respiratory tract and blood, and assess plasma cytokine profiling to study the effects of dexamethasone on both systemic and pulmonary immune cell compartments. In blood samples, dexamethasone is associated with decreased expression of genes associated with T cell activation, including TNFSFR4 and IL21R. We also identify decreased expression of several immune pathways, including major histocompatibility complex-II signaling, selectin P ligand signaling, and T cell recruitment by intercellular adhesion molecule and integrin activation, suggesting these are potential mechanisms of the therapeutic benefit of steroids in COVID-19. We identify additional compartment- and cell- specific differences in the effect of dexamethasone that are reproducible in publicly available datasets, including steroid-resistant interferon pathway expression in the respiratory tract, which may be additional therapeutic targets. In summary, we demonstrate compartment-specific effects of dexamethasone in critically ill COVID-19 patients, providing mechanistic insights with potential therapeutic relevance. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.
BibTeX
@inproceedings{neyton2024distinct,
  author = {Lucile Neyton and Ravi K. Patel and Aartik Sarma and K. Mark Ansel and Stephanie A. Christenson and Michael Adkisson and Walter L. Eckalbar and Lenka Maliskova and Andrew Schroeder and Raymund Bueno and M. Grace Gordon and George C. Hartoularos and Divya Kushnoor and David Lee and Elizabeth McCarthy and Anton Ogorodnikov and Matthew H. Spitzer and Kamir Hiam and Yun S. Song and Yang Sun and Erden Tumurbaatar and Monique G.P. van der Wijst and Alexander Whatley and Chayse Jones and Saharai Caldera and Catherine DeVoe and Paula Hayakawa Serpa and Christina Love and Eran Mick and Maíra Phelps and Alexandra Tsitsiklis and Carolyn Leroux and Sadeed Rashid and Nicklaus Rodriguez and Kevin Tang and Luz Torres Altamirano and Aleksandra Leligdowicz and Michael A. Matthay and Michael R. Wilson and Chun Ye and Suzanna Chak and Rajani Ghale and Alejandra Jáuregui and Deanna Lee and Nguyễn Hoàng Việt and Austin Sigman and Kirsten N. Kangelaris and Saurabh Asthana and Zachary Collins and Ravi K. Patel and Arjun A. Rao and Bushra Samad and Cole Shaw and Tasha Lea and Alyssa Ward and Norman L. Jones and Jeff Milush and Vincent Chan and Nayvin W. Chew and Alexis J. Combes and Tristan Courau and Kenneth H. Hu and Billy Huang and Nitasha Kumar and Salman Mahboob and Priscila Muñoz-Sandoval and Randy Parada and Gabriella C. Reeder and Alan Shen and Jessica Tsui and Beth Shoshana Zha and Wandi S. Zhu and Andrew Willmore and Sidney C. Haller and Kirsten N. Kangelaris and Walter L. Eckalbar and David J. Erle and Matthew F. Krummel and Carolyn M. Hendrickson and Prescott G. Woodruff and Charles Langelier and Carolyn S. Calfee and Gabriela K. Fragiadakis},
  title = {{Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-49756-2},
}
Figure